Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 20531297 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Plaza-Menacho I, et al. (2010) Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance. Oncogene 29, 4648-57 20531297
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S473-p - Akt1 (human)
Orthologous residues
Akt1 (human): S473‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  MCF-7 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  estrogen deprived MCF7 cells
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
GDNF Ret (human) increase
GDNF increase
U0126 GDNF augment treatment-induced increase
wortmannin GDNF inhibit treatment-induced increase
GDNF inhibit treatment-induced increase p38 inhibitor
GDNF inhibit treatment-induced increase JNK inhibitor
rapamycin GDNF inhibit treatment-induced increase partial inhibition

S104-p - ER-alpha (human)
Orthologous residues
ER‑alpha (human): S104‑p, ER‑alpha (mouse): S108‑p, ER‑alpha (rat): S109‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  MCF-7 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  estrogen deprived MCF7 cells
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
GDNF no change compared to control

S106-p - ER-alpha (human)
Orthologous residues
ER‑alpha (human): S106‑p, ER‑alpha (mouse): S110‑p, ER‑alpha (rat): S111‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  MCF-7 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  estrogen deprived MCF7 cells
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
GDNF no change compared to control

S118-p - ER-alpha (human)
Orthologous residues
ER‑alpha (human): S118‑p, ER‑alpha (mouse): S122‑p, ER‑alpha (rat): S123‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  MCF-7 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  estrogen deprived MCF7 cells
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
GDNF Ret (human) increase
GDNF increase
U0126 GDNF inhibit treatment-induced increase slight inhibition
wortmannin GDNF inhibit treatment-induced increase
GDNF no effect upon treatment-induced increase p38 inhibitor, slight inhibition
GDNF no effect upon treatment-induced increase JNKII inhibitor, slight inhibiton
rapamycin GDNF inhibit treatment-induced increase

S167-p - ER-alpha (human)
Orthologous residues
ER‑alpha (human): S167‑p, ER‑alpha (mouse): S171‑p, ER‑alpha (rat): S172‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  MCF-7 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  estrogen deprived MCF7 cells
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
GDNF Ret (human) increase
GDNF increase
U0126 GDNF no effect upon treatment-induced increase
wortmannin GDNF inhibit treatment-induced increase partial inhibition
GDNF no effect upon treatment-induced increase p38 inhibitor
GDNF no effect upon treatment-induced increase JNKII inhibitor
rapamycin GDNF inhibit treatment-induced increase

T202-p - ERK1 (human)
Orthologous residues
ERK1 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  MCF-7 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  estrogen deprived MCF7 cells
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
GDNF Ret (human) increase
GDNF increase
U0126 GDNF inhibit treatment-induced increase
wortmannin GDNF inhibit treatment-induced increase
GDNF no effect upon treatment-induced increase p-38 MAP kinase inhibitor, 2-(4-Chlorophenyl)-4-(4-fluorophenyl)-5-pyridin-4-yl-1,2-dihydropyrazol-3-one
GDNF inhibit treatment-induced increase JNK II inhibitor
rapamycin GDNF no effect upon treatment-induced increase

Y204-p - ERK1 (human)
Orthologous residues
ERK1 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  MCF-7 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  estrogen deprived MCF7 cells
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
GDNF Ret (human) increase
GDNF increase
U0126 GDNF inhibit treatment-induced increase
wortmannin GDNF inhibit treatment-induced increase
GDNF no effect upon treatment-induced increase p-38 MAP kinase inhibitor, 2-(4-Chlorophenyl)-4-(4-fluorophenyl)-5-pyridin-4-yl-1,2-dihydropyrazol-3-one
GDNF inhibit treatment-induced increase JNK II inhibitor
rapamycin GDNF no effect upon treatment-induced increase

T185-p - ERK2 (human)
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  MCF-7 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  estrogen deprived MCF7 cells
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
GDNF Ret (human) increase
GDNF increase
U0126 GDNF inhibit treatment-induced increase
wortmannin GDNF inhibit treatment-induced increase
GDNF no effect upon treatment-induced increase p-38 MAP kinase inhibitor, 2-(4-Chlorophenyl)-4-(4-fluorophenyl)-5-pyridin-4-yl-1,2-dihydropyrazol-3-one
GDNF inhibit treatment-induced increase JNK II inhibitor
rapamycin GDNF no effect upon treatment-induced increase

Y187-p - ERK2 (human)
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  MCF-7 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  estrogen deprived MCF7 cells
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
GDNF Ret (human) increase
GDNF increase
U0126 GDNF inhibit treatment-induced increase
wortmannin GDNF inhibit treatment-induced increase
GDNF no effect upon treatment-induced increase p-38 MAP kinase inhibitor, 2-(4-Chlorophenyl)-4-(4-fluorophenyl)-5-pyridin-4-yl-1,2-dihydropyrazol-3-one
GDNF inhibit treatment-induced increase JNK II inhibitor
rapamycin GDNF no effect upon treatment-induced increase

T183-p - JNK1 (human)
Orthologous residues
JNK1 (human): T183‑p, JNK1 iso2 (human): T183‑p, JNK1 iso3 (human): T183‑p, JNK1 (mouse): T183‑p, JNK1 (rat): T183‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  MCF-7 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  estrogen deprived MCF7 cells
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
GDNF Ret (human) increase
GDNF increase
U0126 GDNF no effect upon treatment-induced increase
wortmannin GDNF no effect upon treatment-induced increase slight inhibition
GDNF no effect upon treatment-induced increase p38 inhibitor
GDNF inhibit treatment-induced increase JNKII inhibitor
rapamycin GDNF inhibit treatment-induced increase slight inhibition

Y185-p - JNK1 (human)
Orthologous residues
JNK1 (human): Y185‑p, JNK1 iso2 (human): Y185‑p, JNK1 iso3 (human): Y185‑p, JNK1 (mouse): Y185‑p, JNK1 (rat): Y185‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  MCF-7 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  estrogen deprived MCF7 cells
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
GDNF Ret (human) increase
GDNF increase
U0126 GDNF no effect upon treatment-induced increase
wortmannin GDNF no effect upon treatment-induced increase slight inhibition
GDNF no effect upon treatment-induced increase p38 inhibitor
GDNF inhibit treatment-induced increase JNKII inhibitor
rapamycin GDNF inhibit treatment-induced increase slight inhibition

S2448-p - mTOR (human)
Orthologous residues
mTOR (human): S2448‑p, mTOR (mouse): S2448‑p, mTOR (rat): S2448‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  MCF-7 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  estrogen deprived MCF7 cells
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
GDNF increase

T180-p - P38A (human)
Orthologous residues
P38A (human): T180‑p, P38A iso2 (human): T180‑p, P38A (mouse): T180‑p, P38A iso3 (mouse): T180‑p, P38A (rat): T180‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  MCF-7 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  estrogen deprived MCF7 cells
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
GDNF increase
GDNF increase
GDNF Ret (human) no effect upon treatment-induced increase siRNA no effect

Y182-p - P38A (human)
Orthologous residues
P38A (human): Y182‑p, P38A iso2 (human): Y182‑p, P38A (mouse): Y182‑p, P38A iso3 (mouse): Y182‑p, P38A (rat): Y182‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  MCF-7 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  estrogen deprived MCF7 cells
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
GDNF increase
GDNF increase
GDNF Ret (human) no effect upon treatment-induced increase siRNA no effect

T412-p - p70S6K (human)
Orthologous residues
p70S6K (human): T412‑p, p70S6K iso2 (human): T389‑p, p70S6K (mouse): T412‑p, p70S6K (rat): T412‑p, p70S6K iso2 (rat): T389‑p, p70S6K (fruit fly): T398‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  MCF-7 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  estrogen deprived MCF7 cells
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
GDNF Ret (human) increase
GDNF increase
U0126 GDNF no effect upon treatment-induced increase slight increase
wortmannin GDNF inhibit treatment-induced increase
GDNF no effect upon treatment-induced increase p38 inhibitor
no effect upon treatment-induced increase JNK II inhibitor
rapamycin GDNF inhibit treatment-induced increase

Y1062-p - Ret (human)
Orthologous residues
Ret (human): Y1062‑p, Ret iso2 (human): Y1062‑p, Ret iso3 (human): Y586‑p, Ret (mouse): Y1063‑p, Ret iso2 (mouse): Y1063‑p, Ret iso4 (mouse): , Ret (rat): Y1063‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  MCF-7 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  estrogen deprived MCF7 cells
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
GDNF increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.